Skip to main content
SpringerLink
Log in

Traitements néo-adjuvants des cancers du sein HER2 positif

  • Conference paper
Cancer du sein

  • 278 Accesses

Abstrait

Les cancers du sein HER2 positif représentent approximativement 20 % de tous les cancers du sein. L’amplification du gène HER2 et la surexpression de la protéine HER2 surviennent tôt dans le développement du cancer et les signaux de transduction associés jouent un rôle important dans la croissance et la survie cellulaire.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Hynes NE, Stern DF (1994) The biology of erbB-2/neu/HER-2 and its role in cancer. Biochem Biophys Acta Rev Cancer 1198: 165–184

    Google Scholar 

  2. Slamon DJ, Clark GM, Wong SG et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182

    Article  PubMed  CAS  Google Scholar 

  3. van de Vijver MJ, Mooi WJ, Peterse JL et al. (1988) Amplification and overexpression of the neu oncogene in human breast carcinomas. Eur J Surg Oncol 14: 111–114

    PubMed  Google Scholar 

  4. Gusterson BA, Gelber RD, Goldhirsch A et al. (1992) Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10: 1049–1056

    PubMed  CAS  Google Scholar 

  5. King CR, Kraus MH, Aaronson SA (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229: 974–976

    Article  PubMed  CAS  Google Scholar 

  6. Menard S, Balsari A, Casalini P et al. (2002) HER-2-positive Breast Carcinomas As a Particular Subset with Peculiar Clinical Behaviors. Clin Cancer Res 8: 520–525

    PubMed  CAS  Google Scholar 

  7. Tagliabue E, Agresti R, Carcangiu ML et al. (2003) Role of HER2 in woundinduced breast carcinoma proliferation. Lancet 362: 527–533

    Article  PubMed  CAS  Google Scholar 

  8. Menard S, Valagussa P, Pilotti S et al. (2001) Response to Cyclophosphamide, Methotrexate, and Fluorouracil in Lymph Node-Positive Breast Cancer According to HER2 Overexpression and Other Tumor Biologic Variables. J Clin Oncol 19: 329–335

    PubMed  CAS  Google Scholar 

  9. Gusterson BA, Gelber RD, Goldhirsch A et al. (1992) Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10: 1049–1056

    PubMed  CAS  Google Scholar 

  10. Paik S, Bryant J, Tan-Chiu E et al. (2000) HER2 and Choice of Adjuvant Chemotherapy for Invasive Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. JNCI Cancer Spectrum 92: 1991–1998

    CAS  Google Scholar 

  11. Muss HB, Thor AD, Berry DA et al. (1994) c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer. The N Engl J Med 330: 1260–1266

    Article  CAS  Google Scholar 

  12. Sliwkowski MX, Lefgren JA, Lewis GD et al. (1999) Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Sem Oncol 26(Suppl 12): 60–70

    CAS  Google Scholar 

  13. Molina MA, Codony-Servat J, Albanell J et al. (2001) Trastuzumab (Herceptin), a Humanized Anti-HER2 Receptor Monoclonal Antibody, Inhibits Basal and Activated HER2 Ectodomain Cleavage in Breast Cancer Cells. Cancer Res 61: 4744–4749

    PubMed  CAS  Google Scholar 

  14. Jackson JG, St CP, Sliwkowski MX et al. (2004) Blockade of epidermal growth factoror heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res 64: 2601–2609

    Article  PubMed  CAS  Google Scholar 

  15. Mohsin SK, Weiss HL, Gutierrez MC et al. (2005) Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 23: 2460–2468

    Article  PubMed  CAS  Google Scholar 

  16. Arnould L, Gelly M, Penault-Llorca F et al. (2006) Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94: 259–267

    Article  PubMed  CAS  Google Scholar 

  17. Clynes RA, Towers TL, Presta LG et al. (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6: 443–446

    Article  PubMed  CAS  Google Scholar 

  18. Gennari R, Menard S, Fagnoni F et al. (2004) Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10: 5650–5655

    Article  PubMed  CAS  Google Scholar 

  19. Pohlmann PR, Mernaugh RL, Miller TW et al. (2006) An active immune network is a surrogate marker for early tumor response to trastuzumab in a preclinical model of breast cancer. Breast Cancer Res Treat 100: S146-Suppl 1

    Google Scholar 

  20. Rusnak DW, Affleck K, Cockerill SG et al. (2001) The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 61: 7196–7203

    PubMed  CAS  Google Scholar 

  21. Gomez HL, Chavez MA, Doval D et al. (2005) A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a firts line treatment in patients with FISH positive advanced or metastatic breast cancer. Proc Ann Meet Am Soc Clin Oncol 23: abstract ASCO

    Google Scholar 

  22. Burris HA, III, Hurwitz HI, Dees EC et al. (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23: 5305–5313

    Article  PubMed  CAS  Google Scholar 

  23. Spector, Neil L, Blackwell, Kimberly L, Hurley J et al. (2006) EGF103009, a phase II of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer: clinical activity and biologic predictors of response. Proc Ann Meet Am Soc Clin Oncol 24: 3s

    Google Scholar 

  24. Geyer CE, Cameron D, Lindquist D et al. (2006) A phase III randomized, open label international study comparing lapatinib and capécitabine vs capecitabine in women with refractory advanced or metastatic breast cancer (EGF100151). Proc Ann Meet Am Soc Clin Oncol 24: abstract ASCO

    Google Scholar 

  25. Marty M, Cognetti F, Maraninchi D et al. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. J Clin Oncol 23: 4265–4274

    Article  PubMed  CAS  Google Scholar 

  26. Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792

    Article  PubMed  CAS  Google Scholar 

  27. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659–1672

    Article  PubMed  CAS  Google Scholar 

  28. Romond EH, Perez EA, Bryant J et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673–1684

    Article  PubMed  CAS  Google Scholar 

  29. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354: 809–820

    Article  PubMed  CAS  Google Scholar 

  30. Slamon DJ, Eiermann W, Robert N et al. (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 94: S5-Suppl 1.

    Google Scholar 

  31. Fisher B, Brown A, Mamounas EP et al. (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B18. J Clin Oncol 15: 2483–2493

    PubMed  CAS  Google Scholar 

  32. Fisher B, Bryant J, Wolmark N et al. (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672–2685

    PubMed  CAS  Google Scholar 

  33. Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97: 188–194

    PubMed  Google Scholar 

  34. Kaufmann M, Hortobagyi GN, Goldhirsch A et al. (2006) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24: 1940–1949

    Article  PubMed  Google Scholar 

  35. Kurosumi M (2004) Significance of histopathological evaluation in primary therapy for breast cancer-recent trends in primary modality with pathological complete response (pCR) as endpoint. Breast Cancer 11: 139–147

    PubMed  Google Scholar 

  36. Bear HD, Anderson S, Smith RE et al. (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24: 2019–2027

    Article  PubMed  CAS  Google Scholar 

  37. Burstein HJ, Harris LN, Gelman R et al. (2003) Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 21: 46–53

    Article  PubMed  CAS  Google Scholar 

  38. Van Pelt AE, Mohsin S, Elledge RM et al. (2003) Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer 4: 348–353

    PubMed  Google Scholar 

  39. Harris L, Burstein HJ, Gelman R et al. (2003) Preoperative trastuzumab and vinorelbine is a highly active, well tolerated reimen for HER2 3+/FISH+ stage II/III breast cancer. Proc Ann Meet Am Soc Clin Oncol 22: 22

    Google Scholar 

  40. Limentani SA, Brufsky AM, Erban JK et al. (2003) Dose dense neodajuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support. Breast Cancer Res Treat 82:(Suppl 1)

    Google Scholar 

  41. Wenzel C, Hussian D, Bartsch R et al. (2004) Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study. J Cancer Res Clin Oncol 130: 1432–1435

    Article  CAS  Google Scholar 

  42. Buzdar AU, Ibrahim NK, Francis D et al. (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23: 3676–3685

    Article  PubMed  CAS  Google Scholar 

  43. Coudert B, Arnould L, Moreau L et al. (2006) Preoperative systemic (neoadjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol 17: 409–414

    Article  PubMed  CAS  Google Scholar 

  44. Hurley J, Doliny P, Reis I et al. (2006) Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 24: 1831–1838

    Article  PubMed  CAS  Google Scholar 

  45. Coudert B, Largillier R, Chollet P et al. (2005) Pathological complete response with neoadjuvant docetaxel, carboplatin and trastuzumab in HER2-positive, locally advanced breast cancer on behalf of the GETN(A) group. Breast Cancer Res Treat 94: S223-Suppl 1

    Google Scholar 

  46. Buzdar A, Valero V, Ibrahim, Nuhad K et al. (2006) Prospective data of additional patients treated with neoadjuvant therapy with paclitaxel followed by FEC chemotherapy with trastuzumab in HER-2 positive operable breast cancer, and an update of initial study population. Breast Cancer Res Treat 94: S223

    Google Scholar 

  47. Bines I, Murad A, Lago S (2003) Multicenter Brazilian study of weekly docetaxel and trastuzumab as primary therapy in stage III, HER-2 overexpressing breast cancer. Proc Ann Meet Am Soc Clin Oncol 22: 67 (abstract 268)

    Google Scholar 

  48. Schiffhauer LM, Griggs JJ, Ahrendt GM (2003) Docetaxel and trastuzumab as primary systemic therapy for HER-2/neu-overexpressing breast cancer. Proc Ann Meet Am Soc Clin Oncol 22: 242

    Google Scholar 

  49. Mehta SR, Schubbert T, Hsiang D (2004) High pathological complete remission rate following neoadjuvant taxane, carboplatin and trastuzumab therapy after doxorubicin and cyclophosphamide in Her-2 positive breast cancer patients. San Antonio Breast Cancer Symposium 2004: abstract 1110

    Google Scholar 

  50. Arnould L, Denoux Y, MacGrogan G et al. (2003) Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br I Cancer 88: 1587–1591

    Article  CAS  Google Scholar 

  51. Diaz NM (2001) Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy. Cancer Control 8: 415–418

    PubMed  CAS  Google Scholar 

  52. Paik S, Bryant J, Tan-Chiu E et al. (2002) Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94: 852–854

    PubMed  Google Scholar 

  53. Roche PC, Suman VJ, Jenkins RB et al. (2002) Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94: 855–857

    PubMed  Google Scholar 

  54. Vincent-Salomon A, MacGrogan G, Couturier J et al. (2003) Re: HER2 testing in the real world. J Natl Cancer Inst 95: 628–629

    PubMed  CAS  Google Scholar 

  55. Vincent-Salomon A, MacGrogan G, Couturier J et al. (2003) Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology 42: 337–347

    Article  PubMed  CAS  Google Scholar 

  56. Arnould L, MacGrogan G, Denoux Y et al. (2006) Étude comparative des techniques IHC et FISH pour la détermination du statut HER-2 dans le cancer du sein métastatique en France: Analyse intermédiaire de l’Etude FISH 2002. Congrès Annuel de la Société de Sénologie et de Pathologie Mammaire, Journée de Sénologie. Deauville 16–18 novembre 2005

    Google Scholar 

  57. Arnould L, Gelly M, Couturier J et al. (2006) Pathological complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER2 amplification in locally advanced breast cancer. Breast Cancer Res Treat 100: S49-Suppl 1

    Article  CAS  Google Scholar 

  58. Torrisi R, Magni E, Dellapasqua S et al. (2006) Trastuzumab and oral vinorelbine (±endocrine therapy) as primary therapy in patients (pts) with HER-2/neu positive breast cancer. Breast Cancer Res Treat 100: S148-Suppl 1

    Google Scholar 

  59. Ferrant E, Gelly M, Guy F et al. (2006) Taux de réponse complète histologique (RCH) par Docetaxel (Taxotere) Trastuzumab (Herceptin) néo-adjuvant dans les cancers du sein HER2-3+ non métastatiques. Bull Cancer 93: 602

    Google Scholar 

  60. Sano M, Tabei T, Suemasu K et al. (2006) Multicenter phase II trial of thriceweekly docetaxel and weekly trastuzumab as preoperative chemotherapy in patients with HER 2-overexpressing breast cancer-Japan East Cancer Center Breast Cancer Consortium (JECBC) 02 Trial. Gan To Kagaku Ryoho 33: 1411–1415

    PubMed  CAS  Google Scholar 

  61. Couturier J, Vincent-Salomon A, Nicolas A et al. (2000) Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol 13: 1238–1243

    Article  PubMed  CAS  Google Scholar 

  62. Cristofanilli M, Boussen H, Baselga J et al. (2006) A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC). Breast Cancer Res Treat 100: S5-Suppl 1

    Google Scholar 

  63. Tanner M, Isola J, Wiklund T et al. (2006) Topoisomerase Ilalpha Gene amplification predicts favorable treatment response to tailored and doseescalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian breast group trial 9401. J Clin Oncol 24: 2428–2436

    Article  PubMed  CAS  Google Scholar 

  64. Knoop AS, Knudsen H, Balslev E et al. (2005) Retrospective analysis of topoisomerase Ha amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23: 7483–7490

    Article  PubMed  CAS  Google Scholar 

  65. Di Leo A, Chan S, Paesmans M et al. (2004) HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat 86: 197–206

    Article  PubMed  Google Scholar 

  66. Thor AD, Berry DA, Budman DR et al. (1998) erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. JNCI Cancer Spectrum 90: 1346–1360

    Article  CAS  Google Scholar 

  67. Paik S, Bryant J, Park C et al. (1998) erB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. JNCI Cancer Spectrum 90: 1361–1370

    CAS  Google Scholar 

  68. Durbecq V, Paesmans M, Cardoso F et al. (2004) Topoisomerase-II (alpha) expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or singleagent docetaxel. Mol Cancer Ther 3: 1207–1214

    PubMed  CAS  Google Scholar 

  69. Coon JS, Marcus E, Gupta-Burt S et al. (2002) Amplification and overexpression of topo-isomerase II (alpha) predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 8: 1061–1067

    PubMed  CAS  Google Scholar 

  70. Slamon DJ, Eiermann W, Robert N et al. (2006) BCIRG 006:2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC?T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC?TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Breast Cancer Res Treat 100: Suppl 1

    Google Scholar 

  71. Lybaert W, Wildiers H, Neven P et al. (2006) Multicenter phase II study of neoadjuvant capecitabine (X), docetaxel (T) ±trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC): preliminary safety and efficacy data. Breast Cancer Res Treat 100: S147-Suppl 1

    Google Scholar 

  72. Agus DB, Gordon MS, Taylor C et al. (2005) Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Onco 23: 2534–2543

    Article  CAS  Google Scholar 

  73. Rimawi MF, Weiss HL, Arpino G et al. (2006) Potent inhibition of EGFR(ErbBl)/HER2 (ErbB2) pathway plus estrogen deprivation is a superior therapeutic combination in ER positive HER2-neu over-expressing breast tumor xenografts. Breast Cancer Res Treat 100: S29-Suppl 1

    Google Scholar 

  74. Moulder SL, Arteaga CL (2003) A Phase I/II Trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpresses HER2/neu (ErbB-2). Clin Breast Cancer 4: 142–145

    Article  PubMed  CAS  Google Scholar 

  75. Rodon J, Beeram M, de Bono JS et al. (2006) Impressive anti-tumor activity of combined erbBl and erbB2 blockade with OSI-774 (erlotinib; E) and trastuzumab (T) in combination with weekly paclitaxel (P) in patients (pts) with trastuzumab refractory breast cancer in a phase I pharmacokinetics (PK) study. Breast Cancer Res Treat 100: S68-Suppl 1

    Google Scholar 

  76. Pegram M, Chan D, Dichman RA et al. (2006) Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. Breast Cancer Res Treat 100: S28-Suppl 1

    Google Scholar 

  77. Nagata Y, Lan KH, Zhou X et al. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117–127

    Article  PubMed  CAS  Google Scholar 

  78. Kim C, Bryant J, Home Z et al. (2006) Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggest pro-apoptotic function of dysregulated cMYC in vivo. Breast Cancer Res Treat 94: S6-Suppl 1

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’oncologie médicale, Centre Georges-François Leclerc, 1, rue du Pr Marion, 21000, Dijon

    B. Coudert, E. Ferrant & F. Mayer

  2. Service d’anatomopathologie, Centre Georges-François Leclerc, 1, rue du Pr Marion, 21000, Dijon

    L. Arnould

  3. Service de radiologie, Centre Georges-François Lederc, 1, rue du Pr-Marion, 21000, Dijon

    F. Guy

  4. Service de chirurgie, Centre Georges-François Leclerc, 1, rue du Pr-Marion, 21000, Dijon

    C. Loustalot

  5. Service de radiothérapie, Centre Georges-François Lederc, 1, rue du Pr-Marion, 21000, Dijon

    K. Peignaux

  6. Département d’oncologie médicale, Centre Georges-François Leclerc, 1, rue du Pr-Marion, 21079, Dijon

    P. Fumoleau

Authors
  1. B. Coudert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Arnould
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Ferrant
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Guy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Loustalot
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K. Peignaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F. Mayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P. Fumoleau
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag France, Paris

About this paper

Cite this paper

Coudert, B. et al. (2007). Traitements néo-adjuvants des cancers du sein HER2 positif. In: Cancer du sein. Springer, Paris. https://doi.org/10.1007/978-2-287-71478-8_40

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-71478-8_40

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-71477-1

  • Online ISBN: 978-2-287-71478-8

Publish with us

Policies and ethics

Search

Navigation